Movement Alert｜Eli Lilly Intraday Rise 5.71%, Q2 Earnings Significantly Beat Expectations with Revenue Guidance Raised

Market Focus

Aug 05

On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded market expectations across all key metrics.

Eli Lilly reported Q2 adjusted EPS of $8.38, beating the consensus estimate of $6.01 by 39.4%, and up from $6.31 a year earlier. Revenue reached $22.97 billion, surpassing the $20.69 billion estimate, representing a 48% year-over-year increase. Core product Mounjaro delivered quarterly revenue of $9.9 billion, up 91% year-over-year and well above the $8.83 billion estimate. Zepbound generated $4.9 billion in revenue, a 46% annual increase.

The company raised its full-year revenue guidance to $85-$87 billion from $82-$85 billion previously, above the FactSet consensus of $85.28 billion. Additionally, CVS Health announced a collaboration with Eli Lilly to expand GLP-1 medication access through transparent pricing and same-day pharmacy pickup, further reinforcing confidence in the demand trajectory. Eli Lilly also announced an additional $4.5 billion investment in manufacturing expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1113809978"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113809978\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113809978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113809978","market":"us","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Intraday Rise 5.71%, Q2 Earnings Significantly Beat Expectations with Revenue Guidance Raised","media":"Market Focus","content":"<p><p>On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded market expectations across all key metrics.</p><p>Eli Lilly reported Q2 adjusted EPS of $8.38, beating the consensus estimate of $6.01 by 39.4%, and up from $6.31 a year earlier. Revenue reached $22.97 billion, surpassing the $20.69 billion estimate, representing a 48% year-over-year increase. Core product Mounjaro delivered quarterly revenue of $9.9 billion, up 91% year-over-year and well above the $8.83 billion estimate. Zepbound generated $4.9 billion in revenue, a 46% annual increase.</p><p>The company raised its full-year revenue guidance to $85-$87 billion from $82-$85 billion previously, above the FactSet consensus of $85.28 billion. Additionally, CVS Health announced a collaboration with Eli Lilly to expand GLP-1 medication access through transparent pricing and same-day pharmacy pickup, further reinforcing confidence in the demand trajectory. Eli Lilly also announced an additional $4.5 billion investment in manufacturing expansion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Intraday Rise 5.71%, Q2 Earnings Significantly Beat Expectations with Revenue Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Intraday Rise 5.71%, Q2 Earnings Significantly Beat Expectations with Revenue Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded market expectations across all key metrics.</p><p>Eli Lilly reported Q2 adjusted EPS of $8.38, beating the consensus estimate of $6.01 by 39.4%, and up from $6.31 a year earlier. Revenue reached $22.97 billion, surpassing the $20.69 billion estimate, representing a 48% year-over-year increase. Core product Mounjaro delivered quarterly revenue of $9.9 billion, up 91% year-over-year and well above the $8.83 billion estimate. Zepbound generated $4.9 billion in revenue, a 46% annual increase.</p><p>The company raised its full-year revenue guidance to $85-$87 billion from $82-$85 billion previously, above the FactSet consensus of $85.28 billion. Additionally, CVS Health announced a collaboration with Eli Lilly to expand GLP-1 medication access through transparent pricing and same-day pharmacy pickup, further reinforcing confidence in the demand trajectory. Eli Lilly also announced an additional $4.5 billion investment in manufacturing expansion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1113809978","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113809978","pubTimestamp":1785936812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"走势提醒|礼来公司盘中上涨5.71%，第二季度盈利大幅超出预期，收入指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On August 5, Eli Lilly rose 5.71% in regular trading, trading at $1195.503/share, with turnover of $802 million. The surge was driven by the company's Q2 financial results that substantially exceeded market expectations across all key metrics.Eli Lilly reported Q2 adjusted EPS of $8.38, beating the consensus estimate of $6.01 by 39.4%, and up from $6.31 a year earlier. Revenue reached $22.97 billion, surpassing the $20.69 billion estimate, representing a 48% year-over-year increase. Core product Mounjaro delivered quarterly revenue of $9.9 billion, up 91% year-over-year and well above the $8.83 billion estimate. Zepbound generated $4.9 billion in revenue, a 46% annual increase.The company raised its full-year revenue guidance to $85-$87 billion from $82-$85 billion previously, above the FactSet consensus of $85.28 billion. Additionally, CVS Health announced a collaboration with Eli Lilly to expand GLP-1 medication access through transparent pricing and same-day pharmacy pickup, further reinforcing confidence in the demand trajectory. Eli Lilly also announced an additional $4.5 billion investment in manufacturing expansion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}